Novartis (ADR) (NVS)
Develops innovative medicines across four therapeutic areas and multiple advanced technology platforms.
$141.26
vs last close+0.28 (+0.20%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12,092 | 11,776 | 12,120 | 12,872 | 13,172 | 13,558 | 13,620 | 14,836 | 14,358 | 13,335 | 13,524 | 14,418 |
| Cost of revenue | 3,117 | 3,022 | 3,096 | 3,173 | 3,234 | 3,324 | 3,227 | 3,322 | 3,539 | 3,542 | 3,459 | 3,681 |
| Gross profit | 8,975 | 8,754 | 9,024 | 9,699 | 9,938 | 10,234 | 10,393 | 11,514 | 10,819 | 9,793 | 10,065 | 10,737 |
| 7,213 | 6,172 | 5,651 | 5,685 | 6,311 | 6,704 | 5,730 | 6,650 | 6,318 | 6,273 | 5,830 | 6,002 | |
| Research & development | 3,925 | 2,567 | 2,421 | 2,367 | 2,392 | 2,842 | 2,366 | 2,727 | 2,944 | 2,837 | 2,740 | 2,759 |
| Selling, general & administrative | 3,091 | 3,444 | 2,840 | 3,091 | 3,134 | 3,501 | 3,058 | 3,442 | 3,308 | 3,436 | 3,140 | 3,243 |
| Other expenses | 197 | 161 | 390 | 227 | 785 | 361 | 306 | 481 | 66 | 0 | −50 | 0 |
| Operating income | 1,762 | 2,582 | 3,373 | 4,014 | 3,627 | 3,530 | 4,663 | 4,864 | 4,501 | 3,521 | 4,235 | 4,735 |
| −210 | −205 | −244 | −173 | −242 | −245 | −256 | −333 | −305 | −303 | −396 | −463 | |
| Interest expense | 222 | 239 | 220 | 246 | 267 | 273 | 270 | 294 | 281 | 304 | 343 | 462 |
| Other non-operating income | −12 | −12 | 23 | −73 | −22 | −30 | −14 | 44 | 24 | −1 | 53 | 0 |
| Income before tax | 1,552 | 2,377 | 3,129 | 3,841 | 3,385 | 3,285 | 4,407 | 4,531 | 4,196 | 3,218 | 3,839 | 4,272 |
| Income tax expense | 39 | −261 | 441 | 595 | 200 | 465 | 798 | 507 | 266 | 814 | 683 | 1,013 |
| Net income from continuing operations | 1,513 | 2,638 | 2,688 | 3,246 | 3,185 | 2,820 | 3,609 | 4,024 | 3,930 | 2,404 | 3,156 | 3,259 |
| Discontinued operations | 250 | 5,842 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 1,761 | 8,480 | 2,688 | 3,246 | 3,189 | 2,818 | 3,606 | 4,041 | 3,928 | 2,409 | 3,156 | 3,266 |
| EPS, basic | $0.85 | $4.14 | $1.32 | $1.60 | $1.58 | $1.42 | $1.83 | $2.07 | $2.04 | $1.26 | $1.65 | $1.71 |
| EPS, diluted | $0.85 | $4.11 | $1.31 | $1.59 | $1.57 | $1.41 | $1.82 | $2.06 | $2.02 | $1.25 | $1.65 | $1.71 |
| Weighted average shares, basic | 2,062 | 2,050 | 2,044 | 2,033 | 2,012 | 1,987 | 1,968 | 1,948 | 1,926 | 1,913 | 1,909 | 1,905 |
| Weighted average shares, diluted | 2,075 | 2,065 | 2,056 | 2,046 | 2,027 | 2,004 | 1,979 | 1,960 | 1,940 | 1,929 | 1,916 | 1,914 |
| EBITDA | 4,885 | 4,182 | 4,664 | 5,249 | 5,614 | 5,188 | 5,831 | 6,076 | 5,841 | 5,073 | 5,410 | 5,936 |
| Depreciation & amortization | 3,111 | 1,588 | 1,314 | 1,162 | 1,965 | 1,628 | 1,154 | 1,256 | 1,364 | 1,551 | 1,228 | 1,201 |
| EBIT | 1,774 | 2,594 | 3,350 | 4,087 | 3,649 | 3,560 | 4,677 | 4,820 | 4,477 | 3,522 | 4,182 | 4,735 |